GlassScriptPhysician profile
Pooja Patel
NPI 1699257105
$3,849.77
in general payments reported to CMS, 2019-2025
26 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $714 · 2023: $811 · 2024: $757 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $713.37 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $455.69 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $343.78 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $244.95 | 2021-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $230.65 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $216.51 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Corium, LLC | $215.79 | 2022-2025 | Azstarys, Adlarity |
| Alkermes, INC. | $153.31 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $151.72 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $132.86 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $119.59 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $110.49 | 2021-2022 | |
| Janssen Biotech, INC. | $99.99 | 2021 | |
| Idorsia Pharmaceuticals US INC | $84.60 | 2023 | Quviviq |
| Galderma Laboratories, L.P. | $81.98 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $75.40 | 2023-2024 | Neurostar Tms Therapy System |
| Axsome Therapeutics, INC. | $72.42 | 2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $45.60 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $45.48 | 2021 | |
| Neurocrine Biosciences, INC. | $43.46 | 2023-2024 | Ingrezza |
| Neos Therapeutics, LP | $41.74 | 2021-2024 | Adzenys Xr-Odt |
| Orexo US, INC. | $39.06 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $38.56 | 2022 | |
| Collegium Pharmaceutical, INC. | $34.15 | 2025 | Jornay Pm |
| W. L. Gore & Associates, INC. | $32.60 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Cvrx, INC. | $26.02 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.